Taysha Gene Therapies(TSHA)
DALLAS, TXBiotechnology
Focus: Taysha Gene Therapies is a Dallas-based public biotechnology company focused on developing adeno-associated virus (AAV) gene therapies for rare neurological and genetic disorders. The company is in clinical-stage development with a specialized, high-risk pipeline targeting severe pediatric and neurological indications.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Taysha Gene Therapies
AI assessmentNot HiringNo open roles listed right now. Follow Taysha Gene Therapies to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Taysha Gene Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$8M
Pipeline & Clinical Trials
None
Leigh SyndromeClinical Trials (1)
NCT05277363A Study of the Natural Course of SURF1 Deficiency
N/AHelp build intelligence for Taysha Gene Therapies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.